SDM for Stroke Prevention in Atrial Fibrillation

Overview

About this study

The objective of this project is to evaluate a treatment decision aid for patients with atrial fibrillation.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Please contact the study team to discuss whether or not you are eligible to participate in a study.

Inclusion Criteria:

  • ≥ 18 years of age
  • Chronic nonvalvular atrial fibrillation deemed at high risk of thromboembolic strokes (CHA2D2-VASc Score ≥ 1, or 2 in women)
  • Able to read and understand (despite cognitive, sensorial, hearing or language challenges) the informed consent document as determined by the study coordinator during consent

Exclusion Criteria:

  • Clinician indicates that patient is not a candidate for a discussion about anticoagulation medication
  •  Cognitive impairments
  • Mechanical values
  • Left appendage occlusion devices (example: Watchman)

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Peter Noseworthy, M.D.

Closed for enrollment

Contact information:

Angela Sivly CCRP

5075387224

Sivly.Angela@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20261276

Mayo Clinic Footer